-
The
innovative Fixed-Dose Combination will help improving the glycemic control
among adult patients with insulin resistance, those whose diabetesis
uncontrolled by metformin; and also those who require addition of Teneliglitptin
and Pioglitazone asseparate drugs.
-
Launched
under the brand name ZitaPlusPio,
thedrug will increase the accessibility of quality drugfor effective diabetes
management.
-
ZitaPlusPio
is the only available DPP4 andGlitazone combination brand in India.
Mumbai,
April 25, 2022:Glenmark Pharmaceuticals Limited (Glenmark), aninnovation-driven global
pharmaceutical company has launched a novelfixed-dose combination (FDC) of a
widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor),Teneligliptin,
with Pioglitazone. This is the only available DPP4 andGlitazone combination
brand in India for adultswithuncontrolledType 2 diabetes. Glenmark has launched
this FDC under the brand name ZitaPlusPio,which contains Teneligliptin (20 mg)
+ Pioglitazone (15 mg), to be taken once a day.
Commenting on the development, Alok Malik, Group Vice President & Head,
India Formulations– Glenmark Pharmaceuticals, said, “Diabetes is a key
area of focus for Glenmark; a pioneer in providing access to the latest
treatment options to diabetic patients in India. We are delighted to introduce
this novelZitaPlusPio, which is
the first of its kind in India; offering a world-class and affordable treatment
option to adult diabetic patients.”
Glenmark
is the first company in India to market the innovative FDC of Teneligliptin+
Pioglitazone, which is approved by the DCGI (Drug Controller General of India).
This fixed dose combination will be useful for patients who require treatment
with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control
reducing Insulin Resistance.
Type 2
diabetics typically face issues of β cell dysfunction and insulin resistance.
Glenmark’s FDC of Teneligliptin +Pioglitazone has the efficacy to tackle
thesetwo most importantpathophysiologieswhich makes the FDCmore effective in
managing uncontrolled Type 2 diabetes. The combination of Teneligliptin+
Pioglitazone will provide a synergistic approach wherein Teneligliptin will
optimally improve β cell sensitivity, and Pioglitazone will effectively reduce
insulin resistance.
Glenmark’s contribution to diabetes treatment
In 2015,
Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor –
Teneligliptin in India, followed by an FDC of Teneligliptin + Metformin. Glenmark has a strong legacy of more than four decades
of progress and innovation. In continuation towards its first time in India
legacy, it has launchedFDC of Teneligliptin + Remogliflozin in 2021.
India is
known to be the diabetes capital of the world. According to the International
Diabetes Federation (IDF), the prevalence of diabetes in India is around 74
million adults, which is expected to increase to 125 million (nearly 70%
increase) by 2045[i].
Out of these, 77% of patients have uncontrolled diabetes[ii].
------End------
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd.
(BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical
company with a presence across Specialty, Generics and OTC businesses. It
focuses on the key therapeutic areas of respiratory, dermatology and oncology.
The company has 10 world-class manufacturing facilities spread across 4
continents and operations in over 80 countries. Glenmark is ranked among the
world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by
Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50
companies in the off-patent sector (Top 50 Generics and Biosimilars Companies
ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on
the Dow Jones Sustainability Index (DJSI), one of the world’s most respected
and widely accepted sustainability benchmarks, under the category of emerging
markets (2021) for the fourth consecutive year in a row. For more information,
visit www.glenmarkpharma.com
